The Medical Advisor

As of March 2024, there are more than 16 published clinical studies of melatonin for treatment and prevention in COVID-19 and the results are promising even when it's given as a late treatment.     On the last day of 2021, Melatonin Research published a  research commentary  discussing an  October 2021 study by Hasan et. al ., which found melatonin significantly lowered mortality when given to severely infected COVID patients. According to the authors: “In a single-center, open-label, randomized clinical trial, it was observed that melatonin treatment lowered the mortality rate by 93% in severely-infected COVID-19 patients compared with the control group. This is seemingly the first report to show such a huge mortality reduction in severe COVID-19 infected individuals with a simple treatment. If this observation is confirmed by more rigorous clinical trials, melatonin could become an important weapon to combat this pande

In 2011, Lesley Yates, a vibrant mother and teacher’s aide, suffered a medical crisis after receiving a routine antibiotics prescription for a suspected urinary tract infection. The aftermath left her with severe tendon injuries, culminating in a premature transition to permanent disability at the age of 54. Several doctors and experts dismissed her symptoms, Ms. Yates told The Epoch Times. Her story highlights the critical but underreported adverse effects associated with fluoroquinolone antibiotics—and the medical problems that arise in the absence of clear warnings of their risks. “I feel like a 90-year-old in a 50-year-old body,” Ms. Yates told The Epoch Times. (The Epoch Times) Fluoroquinolones: Potency and Risk Fluoroquinolones, including ciprofloxacin (Cipro), levofloxacin (Levaquin), and moxifloxacin (Avelox), are powerful antibiotics designed to battle various bacterial infections—from urinary tract and respiratory infections to dermatological conditions. Fluoroquinolones are